Natco Pharma receives USFDA tentative approval for Trabectedin for Injection
Capital MarketNatco Pharma announced that the U.S. Food and Drug Administration has granted tentative approval to its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis ) for the 1mg/vial presentation.
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
